Extension Study to Evaluate Long-Term Effects of Luspatercept in Patients With Myelodysplastic Syndromes (MDS) (A536-05/MK-6143-003)
Clinical trial NCT02268383 · COMPLETED
Trial details
- NCT number
- NCT02268383
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-09
- Primary completion
- 2020-03-19
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.